NewAmsterdam Pharma NAMS
NASDAQ NAMS
$24.16 -0.16 (-0.66%)
At close: Oct 1, 2026 · 4:00 PM EDT

NewAmsterdam Pharma (NAMS) Other Non-Current Liabilities (2022 - 2024)

Updated

NewAmsterdam Pharma (NAMS) recorded Other Non-Current Liabilities of $18.81 million in Q3 2024, up 40.4% from the prior quarter.

Analysis

NewAmsterdam Pharma (NAMS) Other Non-Current Liabilities (2022 - 2024) Analysis & Trends

At the end of FY2023, NewAmsterdam Pharma reported Other Non-Current Liabilities of $7.79 million, up 3.5% from FY2022.

  • Across earlier years, Other Non-Current Liabilities came in at $7.52 million in FY2022.
  • Per Business Quant, the preceding three quarters came in at $13.39 million (Q2 2024), $16.49 million (Q1 2024) and $7.79 million (Q4 2023).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 NewAmsterdam Pharma 2.86 Bn 2.86 Bn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2024 18.81 Mn
Jun 30, 2024 13.39 Mn
Mar 31, 2024 16.49 Mn
Dec 31, 2023 7.79 Mn
Jun 30, 2023 8.22 Mn
Dec 31, 2022 7.20 Mn
API Access

NewAmsterdam Pharma Other Non-Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-non-current-liabilities&ticker=NAMS&period=max&api_key=YOUR_API_KEY